deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02737501

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Sponsor: Ariad Pharmaceuticals

Conditions Advanced Malignancies Carcinoma Lung Cancer Non-small Cell Lung Cancer
Interventions Brigatinib Crizotinib
Updated 17 times since 2017 Last updated: Jul 27, 2021 Started: May 26, 2016 Primary completion: Jul 28, 2020 Completion: Jan 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Advanced Malignancies and Carcinoma, this trial is completed. The trial is conducted by Ariad Pharmaceuticals and has accumulated 17 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Sep 2020 · 16 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  3. May 2019 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  9. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  10. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ariad Pharmaceuticals
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alicante, Spain , Amsterdam, Netherlands , Aurora, United States , Avellino, Italy , Aviano, Italy , Badalona, Spain , Barcelona, Spain , Bari, Italy , Bellflower, United States and 69 more locations